PINNED
PINNED
Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
Articles
New horizons in next-generation small molecule kinase inhibitors
In the pre-imatinib (Glivec®) era, two out of three patients died within five years from chronic myeloid leukemia and there was no hope for a curative treatment. Imatinib’s introduction in 2001 marked a breakthrough – as the first approved kinase inhibitor, it was a game-changer in cancer therapy and revolutionised…
Pharmacometabolomics as the key to personalised medicine
Blanketed administration of drugs to all populations assumes that all patients respond similarly. Despite pharmaceutical companies’ efforts to develop drugs with large therapeutic windows, there are often and inevitably subpopulations of individuals who will either not respond to therapy or will respond with adverse effects...
Mechanism-informed phenotypic screening – the missing link for cancer drug discovery?
Cancer cells exhibit huge phenotypic diversity, with many well-defined phenotypes, such as invasion, deregulated proliferation and immune evasion, contributing to disease outcomes, making them uniquely amenable to phenotypic screening1...
Leaving EU could be a setback for Life Sciences in the UK
8 June 2016 | By Dr Alexander Moscho, Bayer UK & Ireland CEO
In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines...
JLINX: a first of its kind European incubation model to catalyse scientific innovation
31 May 2016 | By Kurt Hertogs, PhD, Head of JLINX, Johnson & Johnson Innovation
Kurt Hertogs discusses JLINX - a new initiative that aims to catalyse scientific innovation...
PIM/FLT3 dual inhibition
13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.
In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...
Soligenix on IDR technology and SGX942
10 May 2016 | By Victoria White, Digital Content Producer
We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...
Advancing FLIP inhibitors for the treatment of NSCLC
26 April 2016 | By Victoria White, Drug Target Review
In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...
The threat of antibiotic resistance
25 April 2016 | By Victoria White, Drug Target Review
We've created an infographic on the threat of antibiotic resistance, highlighting some of the recommendations made by the Review on Antimicrobial Resistance to date...
Demands in medical automation technology brings two prominent players close
22 April 2016 | By Snehal Chougule, Allied Market Research
Here, Snehal Chougule discusses Trajan's recent investment in automation solution company, LEAP Technologies Inc...
Delving into drug discovery in Drug Target Review
12 April 2016 | By Caroline Richards, Editor, Drug Target Review
Here, Caroline Richards, Editor of Drug Target Review, discusses the publication and the opportunities available to authors...
Our EU referendum poll: the results are in
31 March 2016 | By Victoria White, Drug Target Review
We asked readers of if they agreed with BIA that the UK pharmaceutical industries are stronger in the EU. The results of that poll are now in...
Explaining CAR T-cell therapy
23 March 2016 | By Dr John Maher, Principal Investigator, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy’s and St Thomas’ and Kings College London
Here, Dr John Maher of the NIHR BRC at Guy's and St Thomas' and Kings College London discusses CAR T-cell therapy and the exciting frontier the technique has opened up in the battle against cancer...
Drug Target Review – Issue #1 2016
17 March 2016 | By Drug Target Review
Included in this issue: Microfluidics, Protein Expression, Drug Targets, Biomarkers, Oncology, Assays, Antibodies, and much more...
Antibodies In-Depth Focus 2016
In this Antibodies In-depth Focus: Antibody fragment technology and avian IgY antibodies: a powerful combination; plus the challenges with antibody-based targeting of VEGF...
